S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

$1.59
+0.03 (+1.92%)
(As of 03/28/2024 ET)
Today's Range
$1.53
$1.65
50-Day Range
$1.42
$2.30
52-Week Range
$1.33
$3.92
Volume
26,051 shs
Average Volume
60,127 shs
Market Capitalization
$27.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Exagen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
277.4% Upside
$6.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.30mentions of Exagen in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$24,417 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.67 out of 5 stars

Medical Sector

73rd out of 939 stocks

Medical Laboratories Industry

4th out of 20 stocks

XGN stock logo

About Exagen Stock (NASDAQ:XGN)

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Stock Price History

XGN Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
Exagen Full Year 2023 Earnings: Beats Expectations
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Here's what to expect from Exagen's earnings
Exagen reports Q4 results
XGN Apr 2024 2.500 put
See More Headlines
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
3/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
199
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+277.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,690,000.00
Pretax Margin
-45.02%

Debt

Sales & Book Value

Annual Sales
$52.55 million
Book Value
$1.33 per share

Miscellaneous

Free Float
10,893,000
Market Cap
$27.41 million
Optionable
Optionable
Beta
1.23
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Tina S. Nova Ph.D. (Age 70)
    Executive Chairman of Board
    Comp: $65k
  • Mr. John Aballi (Age 39)
    CEO, President & Director
    Comp: $558.84k
  • Mr. Kamal Adawi M.S. (Age 45)
    MBA, CFO & Corporate Secretary
    Comp: $483.28k
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 55)
    Senior Vice President of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
  • Dr. Michael I. Nerenberg M.D. (Age 69)
    Chief Medical Officer

XGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Exagen stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings
or view top-rated stocks.

What is Exagen's stock price target for 2024?

2 brokerages have issued 1-year target prices for Exagen's stock. Their XGN share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 277.4% from the stock's current price.
View analysts price targets for XGN
or view top-rated stocks among Wall Street analysts.

How have XGN shares performed in 2024?

Exagen's stock was trading at $1.99 at the start of the year. Since then, XGN stock has decreased by 20.1% and is now trading at $1.59.
View the best growth stocks for 2024 here
.

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our XGN earnings forecast
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.02. The firm had revenue of $13.77 million for the quarter, compared to analysts' expectations of $11.43 million. Exagen had a negative trailing twelve-month return on equity of 80.28% and a negative net margin of 45.08%. During the same period last year, the company earned ($0.58) EPS.

What guidance has Exagen issued on next quarter's earnings?

Exagen updated its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.0 million-$54.0 million, compared to the consensus revenue estimate of $54.1 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

When did Exagen IPO?

Exagen (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Who are Exagen's major shareholders?

Exagen's stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.82%), Wasatch Advisors LP (4.99%), Stonepine Capital Management LLC (3.93%), Perkins Capital Management Inc. (2.98%), Nantahala Capital Management LLC (0.57%) and Dimensional Fund Advisors LP (0.21%). Insiders that own company stock include James L L Tullis, John Aballi, Kamal Adawi, Mark Hazeltine and Wendy S Johnson.
View institutional ownership trends
.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XGN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners